News
Articles, industry coverage and commentary
News
Articles, industry coverage and commentary
News
-
Precision for Medicine Honored in Every Category of 2023 CRO Leadership Awards
Precision for Medicine announces its wide recognition in the 2023 CRO Leadership Awards. The company has been honored in all five categories: Capabilities, Compatibility, Expertise, Quality, and Reliability, showcasing its exceptional performance in the CRO industry.
-
Precision for Medicine Expands Advanced Tissue Profiling and Genomic Capabilities with new Houston Laboratory
Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics HOUSTON, TX, April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell […]
-
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity. [Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced […]
-
Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
BETHESDA, Md., November 3, 2022 – Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and […]
-
Advaxis Presents Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503 being […]
-
Precision for Medicine Receives Top Recognition in CRO Leadership Awards
BETHESDA, MD, May 3, 2022 – Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the company has received four awards from Clinical Leader and Life Science Leader’s 2022 […]
-
Deep Lens Announces Launch of Real Time Feasibility Offering to Assist in Oncology Clinical Trial Design and Site Selection
Columbus, OH – December 7, 2021 – Deep Lens, a digital healthcare company focused on revolutionizing the oncology clinical trial recruitment process through artificial intelligence solutions, today announced the launch of its Real Time Feasibility offering, a new HIPAA-compliant tool designed to identify eligible patients and select the most effective […]
-
Precision for Medicine CIR (French Research Tax Credit) Accreditation Updates
PARIS, FRANCE – 10 November 2022 — Precision for Medicine, the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, today announced that it has received updated CIR accreditation from the French Ministry of Higher Education […]
-
Precision for Medicine Announces Partnership with Trialbee to Expand and Accelerate Clinical Trial Recruitment
Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine MALMO, SWEDEN & BETHESDA, MD — August 5, 2021 – Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are […]
-
Precision Medicine Group Significantly Expands Cell and Gene Therapy Expertise with Acquisition of Project Farma
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—’PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION BETHESDA, MD—January 14, 2021—Precision Medicine Group (“PMG”) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that […]
